Lynparza (olaparib)

Numéro de dossier de l’APP: 21464
État des négociations:
Active Negotiation
Indication(s):
Monotherapy for the treatment of adult patients with mCRPC & deleterious or suspected deleterious germline/somatic mutations in the HRR genes BRCA or ATM who have progressed following prior treatment with a NHA
Promoteur/fabricant:
AstraZeneca Canada Inc.
Numéro de projet de l’ACMTS:
PC0223-000
Lettre-contrat de l’APP:
Conclusion du processus de négociation:
Not Applicable